Additionally, GLP-1 RAs users consistently demonstrated a statistically significant lower risk of cardiac arrest and cardiogenic shock (aHR = 0.30, p = 0.001), dialysis dependence (aHR = 0.49, p < 0.001) and eGFR less than 15 mL/min/1.73 m2 (aHR = 0.77, p < 0.001). The gene discussed is GLP1R; the disease is cardiac arrest.